Profile cover photo
Profile photo
Protalex, Inc.
4 followers -
Protalex, Inc. (OTCQB: PRTX) is focused on the development of a class of drugs for treating a wide array of autoimmune and inflammatory diseases.
Protalex, Inc. (OTCQB: PRTX) is focused on the development of a class of drugs for treating a wide array of autoimmune and inflammatory diseases.

4 followers
About
Protalex, Inc.'s posts

Post has attachment
President & CEO, Arnold P. Kling issued a Letter to Shareholders providing a business update. "Protalex started 2017 with several advances to our global clinical development programs of our lead product, PRTX-100, a highly-purified form of Staphylococcal protein A (SpA), as a potentially safe and effective new treatment for autoimmune diseases, that position us for continued advancement throughout the balance of the year and beyond," noted Kling. Click to read the full Shareholder Letter.

Post has attachment
Protalex significantly strengthens global intellectual property portfolio with the addition of six key international patents protecting and expanding use for PRTX-100. “We continue to invest in expanding our global intellectual property portfolio as part of our commitment to broadly protect our proprietary immunomodulatory SpA technology. We are fortifying our patent estate to support our comprehensive strategy for the development and commercialization of PRTX-100 in a variety of autoimmune and inflammatory diseases,” stated Protalex President, Arnold Kling.

Post has attachment
Protalex provided an update on its U.S. Phase 1/2 and European Phase 1b studies of PRTX-100 in adults with persistent, chronic Immune Thrombocytopenia (ITP). Dr. Richard Francovitch, Protalex’s VP ITP Programs, commented, “to meet the challenge of patient enrollment associated with a rare disease like ITP, especially in a population that has not responded adequately to current therapies, we have expanded the number of clinical sites markedly. With this expansion, we will soon have more than 20 sites worldwide for patient enrollment. We look forward to completing the second cohorts in the 202 and 203 studies and to advancing to the next cohort in each study.”

This Friday, May 20th, 2016 is World Autoimmune Arthritis Day. Join us in raising awareness for the 1.5 million Americans living with rheumatoid arthritis.

Post has attachment
American College of Rheumatology shares a few quick facts about rheumatoid arthritis. http://bit.ly/1Nyf1VX

Post has attachment
Our lead product candidate PRTX-100 has shown to be effective in elevating platelet counts in murine models of human ITP. http://bit.ly/1XOe9v7

Post has attachment

Post has attachment
Up to the minute information can be found on our Twitter page. Follow us today. http://bit.ly/1K86EHX

Post has attachment

Post has attachment
Wait while more posts are being loaded